

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Page 1 of 1

Application Number

10/799999

Filing Date

March 12, 2004

First Named Inventor

MILLER, RICHARD L.

Confirmation Number

8776

Attorney Case Number

58351US004

## U.S. Patent Documents

Exam. Init.*	Cite No.	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Doc. Number-(Kind Code if Known)			
	A1	US- 5,736,553	04-07-1998	Wick et al.	
	A2	US- 6,365,166	04-02-2002	Beaurline et al.	
	A3	US- 6,486,186	11-26-2002	Fowler et al.	
	A4	US- 6,706,728	03-16-2004	Hedenstrom et al.	
	A5	US- 6,743,920	06-01-2004	Lindstrom et al.	
	A6	US- 6,756,382	06-29-2004	Coleman et al.	
	A7	US- 6,818,650	11-16-2004	Griesgraber	
	A8	US- 6,825,350	11-30-2004	Crooks et al.	
	A9	US- 2003/0161797	08-28-2003	Miller et al.	
	A10	US- 2004/0091491	05-13-2004	Kedl, et al.	
	A11	US- 2004/0132079	07-08-2004	Gupta, et al.	
	A12	US-			

## Foreign Patent Documents

Exam. Init.*	Cite No.	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation (Check if yes)
		Ctry. Code	Number-KindCode (if known)				
	B1	WO	02/08595	01-31-2002			

## OTHER DOCUMENTS

Exam. Init.*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	Translation (Check if yes)
	C1	Gibson et al., <i>Cell Immunol.</i> 218(1-2):74-86 (2002)	
	C2	Salasche, et al., "Cycle Therapy of Actinic Keratoses of the Face and Scalp with 5% Topical Imiquimod Cream: An Open-Label Trial, <i>Am Acad Dermatol</i> , October 2002, pp. 571-577	
	C3	Stanley, Imiquimod and the Imidazoquinolones: Mechanism of Action and Therapeutic Potential, 2002 Blackwell Science Ltd., <i>Clinical and Experimental Dermatology</i> , vol. 27, pp. 571-577	
	C4		

\*Examiner: /Kendra Carter/

Date Considered: 06/27/2011

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Information Disclosure Statement)